

nucleai

Short profile Nucleai Ltd.

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Medical field	Oncology, Pathology
Product	Nucleai Precision IO Biomarker (Advanced technologies (AI), Medical Device, Diagnostics)
Growth stage	Proof of Concept
Founders	Avi Veidman (CEO, Co-Founder), Eliron Amir (COO, Co-Founder), Lotan Chorev (VP R&D, Co-Founder)

Description of product:

The product is a decision support system for the oncologist. AI-based tissue modeling engine intended to identify and segment various types in pathology slides including tumor, benign, and necrotic tissues. The engine also detects different types of cells such as tumor cells and various types of immune cells.

Project goal:

The goal is to validate Nucleai's immuno-therapy prediction capabilities with a leading cancer center and to achieve results that can be published in high impact peer reviewed journals.

Project type:

By the time we start the work with the potential partner hospitals we expect to already have a predictive biomarker that was developed retrospectively. Therefore, through the work with the partner hospitals we could validate the accuracy of our biomarker either retrospectively or prospectively (in an observational fashion) and publish it in scientific literature. Estimated validation time: 3 months.

The structure will include receiving retrospective clinical and histological data of patients treated with immunotherapy, together with pathology and oncology consultancy from the hospital. Nucleai will analyze the data and provide the algorithmic and prediction scoring results. The clinical analysis of the results will be performed with the relevant physician. Estimated project duration: 6 months.



Eligible by the IIA



lotan@nucleaimd.com



Lotan Chorev: 972544437066



www.nucleaimd.com





CHARITÉ
UNIVERSITÄTSMEDIZIN DRESDEN

BIH Berlin Institute
of Health
Charité & MDC

& רשות החדשנות
Israel Innovation
Authority

